topic

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Rachel E Sanborn, Muhammad Furqan, Doug Laux, Manish Sharma, Daniel Olson, David Berz, Ralph J Hauke, Erminia Massarelli, Conor Steuer, Elizabeth Davis, Wade T Iams, Jonathan Thompson, John Hamm, Vasily Andrianov, Brianne O’Neill, Yaiza Diaz De Durana, Anthony W Tolcher

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A844; DOI: 10.1136/jitc-2023-SITC2023.0748
749 Early phase oncology experience on the use of an oncolytic adenovirus encoding for TNFa and IL-2 for the treatment of solid tumors – Interim results
Joao Santos, Inge Svane, Katriina Peltola, Tuomo Alanko, Riitta Korpisaari, Susanna Juteau, Marjut Jaakkola, Jorma Sormunen, Juha Kononen, Eva Ellebaek, Tine Monberg, Marco Donia, Amir Khammari, Brigitte Dreno, Santeri A Pakola, James Clubb, Elise Jirovec, Dafne CA Quixabeira, Tatiana Kudling, Lyna Haybout, Victor Cervera-Carrascon, Claudia Kistler, Suvi Sorsa, Riikka Havunen, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A845; DOI: 10.1136/jitc-2023-SITC2023.0749
750 A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers
J Eva Selfridge, Nataliya Uboha, Yvonne Saenger, Jorge Chaves, Lei Zheng, John Powderly, Dae Won Kim, Olatunji Alese, Siqing Fu, Jun Gong, Nashat Gabrail, Jin Zhaohui, Tanios Bekaii-Saab, Angela Alistar, Laura Agensky, Apollina Goel, Steven Margossian, Steve Quayle, Matteo Levisetti

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A846; DOI: 10.1136/jitc-2023-SITC2023.0750
751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor
David Sommerhalder, Marcus Noel, Scott Boiko, Scott Daigle, Xinyan Zhang, Patricia Fraser, Amanda Hoerres, Nawaid Rana, Esha A Gangolli, Frank G Basile, Bhaskar Srivastava, Sunil Sharma, Rama Balaraman, Martin Gutierrez

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A847; DOI: 10.1136/jitc-2023-SITC2023.0751
752 Developing biomarkers for bexmarilimab, a novel macrophage-guided immunotherapy, in advanced solid tumors to select patients and confirm mechanism of action
Alexander J Spicer, Elisa M Vourninen, Juho M Jalkanen, Marie-Louise Fjallskog, Jussi Koivunen, Teppo Huttunen, Petri Bono, Maija Hollmen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A848; DOI: 10.1136/jitc-2023-SITC2023.0752
753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors
David R Spigel, Costantine Albany, Michael Chisamore, Kelly D Moynihan, Christopher DelNagro, Jennifer Visich, Matt Axt, Xiaohan Liu, Mark Sayles, Andrea Pirzkall, Elizabeth I Buchbinder

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A849; DOI: 10.1136/jitc-2023-SITC2023.0753
754 Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC)
David R Spigel, Erika Hamilton, Babar Bashir, Usama Gergis, Hemant S Murthy, Saranya Chumsri, Yazan Migdady, Jennifer Specht, Lubna N Chaudhary, Haven Garber, Chul Kim, Hirva Mamdani, Sarah Fitzsimmons, Bishwa J Ganguly, Hajime Hiraragi, Helle Jensen, Yeonhee Kim, Mary C Lessig, Heidi Gillenwater

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A850; DOI: 10.1136/jitc-2023-SITC2023.0754
755 DEKA-1 a dose-finding Phase 1 trial: observing safety and biomarkers using DK2¹⁰ (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors failing systemic therapy
Alexander I Spira, Douglas Orr, Aurélien Marabelle, Elizabeth C Moser, Deb Kientop, John Mumm

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A851; DOI: 10.1136/jitc-2023-SITC2023.0755
756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors
Alexander I Spira, Michael S Gordon, Jason Henry, Sandip P Patel, Kartik Sehgal, Shiraj Sen, Randy Sweis, Marsha Crochiere, Shui He, Sondra Smyrnios, Dipali Unadkat, Bin Zhang, Anthony W Tolcher

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A852; DOI: 10.1136/jitc-2023-SITC2023.0756
757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab
Kristoffer Staahl Rohrberg, Zsuzsanna Papai, Ana Carneiro, Istvan Lang, Jeffrey Yachnin, Sean Lim, Lars Ny, Rikke H Lovendahl Eefsen, Harriet Walter, Edvard Abel, Kirstie Cleary, Robert Oldham, Mark Cragg, Marie Borggren, Susanne Gertsson, Petra Holmkvist, Ingrid Karlsson, Linda Martensson, Jan Anders Nilsson, Johan E Wallin, Michael Chisamore, Bjorn Frendeus, Ingrid Teige, Andres McAllister

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A853; DOI: 10.1136/jitc-2023-SITC2023.0757

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages